Accuray Incorporated (ARAY) reported second-quarter fiscal 2025 earnings per share of 2 cents against the year-ago period’s loss of 10 cents. The bottom line surpassed the Zacks Consensus Estimate by 300%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenues in DetailAccuray registered quarterly revenues of $116.2 million, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 4.7%.The overall top-line growth was driven by robust growth in product revenue and solid ...

Financial Data and Key Metrics Changes - Revenue for the quarter increased by 8% year-over-year, reaching $116 million, with product revenue growing by 19% to $61 million [10][24] - Adjusted EBITDA for the quarter was $9.6 million, significantly up from $2 million in the prior year, driven by higher shipments and operational efficiencies [31][10] - The overall gross margin improved to 36.1% from 33.5% in the prior year, attributed to pricing and operational efficiencies [27][10] Business Line Data and Key Metrics Changes - Product revenue growth was driven by strong demand for the CyberKnife system, which saw revenue growth of over 50% year-over-year [12][10] - Service revenue for the quarter was $55 million, down 1% year-over-year, but adjusted for one-time items, it would have been up 2% [24][10] - The service business is expected to grow as the installed base increases, contributing to long-term revenue growth [18][10] Market Data and Key Metrics Changes - In China, revenue grew over 50% year-over-year, with significant contributions from the Tomo C System and a strong performance from the joint venture partner [13][10] - Japan experienced over 40% revenue growth, maintaining a number two market share position [16][10] - EIMEA region saw 7% orders growth, with balanced contributions from both developed and emerging markets [11][10] Company Strategy and Development Direction - The company aims to innovate and expand its service solutions business while improving patient access to radiotherapy in developing markets [9][10] - A focus on operational efficiencies and pricing actions is expected to enhance margins and long-term profitability [9][10] - The introduction of new products like the Helix platform is part of the strategy to capture market share in emerging markets [11][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $463 million to $475 million for fiscal 2025, raising expectations from previous guidance [21][34] - The company anticipates a gradual recovery in the U.S. market in the second half of the fiscal year, with key installations already in progress [50][10] - Management is closely monitoring macroeconomic factors, including inflation and tariffs, but believes the risks are minimal for the second half of the year [33][54] Other Important Information - The company welcomed a new Chief Operations Officer, Leonel Peralta, to enhance operational excellence and productivity [20][10] - The company is focused on addressing its capital structure and refinancing needs to ensure flexibility for future growth [33][10] Q&A Session Summary Question: Details on China revenue growth and sustainability - Management highlighted strong performance in China, attributing it to a strategic joint venture partner and a robust product portfolio, with expectations for continued demand [42][44] Question: Revenue number from China - Management indicated that specific revenue numbers could be shared in one-on-one calls [46] Question: Confidence in U.S. market recovery and macroeconomic factors - Management expects gradual recovery in the U.S. market, with visibility on orders already in the backlog, and is monitoring inflation and tariffs closely [50][54] Question: Performance in Japan and future opportunities in India - Management noted strong performance in Japan and anticipated growth in India, particularly with the upcoming regulatory approval for the Helix product [61][64]

Accuray (ARAY) reported $116.17 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 8.3%. EPS of $0.02 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $110.95 million, representing a surprise of +4.71%. The company delivered an EPS surprise of +300.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this radiation oncology company would post a loss of $0.04 per share when it actually produced a loss of $0.04, delivering no surprise.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33301 ACCURAY INCORPORATED Delaware 20-8370041 (State or other jurisdiction of incorporation or organization) (IRS Employer Identificat ...

MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024.Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidance Total net revenue was $116.2 million, an increase of 8 percent year-over-year Net income was $2.5 million compared to a net loss of $9.6 million in the prior year period Adjusted EBITDA was $9.6 million compared to $2.0 million in the prior year ...

"Our strong Q2 performance reflects outstanding execution of our strategies of advancing radiotherapy care, expanding patient access and improving margin performance of the business. We continue to see growing demand for our solutions from our increased commercial presence particularly in fast-growing emerging markets evidenced by the strong momentum in Tomo C System deliveries this quarter, as well as breakthrough wins of our new Helix system, following CE mark in the first fiscal quarter," said Suzanne Wi ...

Company Milestone - Accuray Incorporated announced the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System at Shandong Cancer Hospital and Institute, marking a significant milestone for the company in addressing the underserved Chinese radiation therapy market [1] - The Tomo C System, developed through the CNNC-Accuray joint venture, has expanded clinical capabilities and enabled potentially curative treatment for more cancer patients in China [1] Market Opportunity - The number of new cancer cases in China is expected to increase by 47% to 7.1 million in 2045, up from 4.8 million in 2022, highlighting the growing demand for advanced radiotherapy technology [2] - The Tomo C System is designed to meet the needs of the underserved Chinese radiation therapy market, with the potential to significantly increase treatment capacity and improve patient outcomes [1][5] Product Impact - The Tomo C System, based on the helical TomoTherapy® platform, enables the treatment of an average of 95 patient fractions per day, significantly increasing the hospital's capacity to provide innovative and effective cancer care [5] - The system integrates helical imaging, advanced treatment planning, and centralized data management to facilitate fast, ultra-precise treatments, allowing more patients to receive care each day [5] Strategic Collaboration - Shandong Cancer Hospital and Institute, a top cancer care center in China, serves over 400,000 patients annually and collaborates with global leaders such as MD Anderson Cancer Center, reinforcing its commitment to innovation and excellence in cancer treatment [4] - The introduction of the Tomo C System expands Accuray's product portfolio in China and reinforces its commitment to providing advanced tools for precision radiotherapy [4][5] Leadership Perspective - Suzanne Winter, President and CEO of Accuray, emphasized the system's ability to treat a wide range of cancer types and its potential to meaningfully increase treatment capacity, enabling more patients to receive care daily [3] - Prof. Yu, President of Shandong Cancer Hospital, highlighted the transformative impact of the TomoTherapy platform and the Tomo C System's role in advancing precision radiotherapy and supporting the "Healthy China Initiative" [5]

MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025.The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one wee ...

MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accur ...